More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Dacomitinib Anhydrous [1110813-31-4]

Dacomitinib Anhydrous [1110813-31-4]

Research Use Only
D004098
LKT Laboratories
Estimated Purity≥99%
Product group Chemicals
€ 455,00
100 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    Dacomitinib Anhydrous [1110813-31-4]
  • Delivery Days Customer
    7
  • Certification
    Research Use Only
  • Estimated Purity
    ≥99%
  • Format
    DMSO 75 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL
  • Scientific Description
    EGFR inhibitor.; PF00299804 Anhydrous
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200

References

  • Gonzales A., Hook K., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 7(7):1880-9 (2008). PMID: 18606718. Nagano T., Tachihara M., et al. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Drugs Today (Barc). 55(4):231-236 (2019). PMID: 31050691. Momeny M., Esmaeili F., et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cell Oncol. 2019. PMID: 31025257.